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ous data collection methods; to provide an interactive fo-
rum for discussing recommendations for the use of each
method; and to discuss the implications that alternative
measurement strategies may have on reported results.
PARTICIPANTS WHO WOULD BENEFIT: This ses-
sion is directed at individuals who are responsible for the
design and conduct of pharmacoeconomic evaluations.
Individuals who need to interpret study results will also
benefit from this workshop.
Pharmacoeconomic studies are often designed without
the appropriate concern for, or justification of, the data
collection method used. Previous research has focused
mainly on what data to collect rather than how to col-
lect the data. This current research focuses on the issue
of study validity through the use of various data collec-
tion strategies. This workshop will discuss the appropri-
ate application of each strategy and provide recommen-
dations for the employment of particular data collection
methods in the context of specific studies. Methodolo-
gies to be discussed include office-based self-administra-
tion, patient diaries, face-to-face interviews (written and
oral), telephone interviews (personal and CATI), and
postal surveys. The research presented here augments
earlier research by informing researchers of potential is-
sues with data collection techniques on resource utiliza-
tion collection.
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WORKSHOP OBJECTIVE: Advances in treatment for
schizophrenia and the development of evidence-based
standards of care demand better methods for population-
based research on this disease and routine assessment of
treatment outcomes in systems of care. The purpose of
this workshop is to introduce the Schizophrenia Care and
Assessment Program Health Questionnaire (SCAPHQ),
a brief instrument to measure the clinical and functional
outcomes of care for schizophrenia. We will describe the
rationale for the instrument, the process of its develop-
ment, and its scope of measurement. We will discuss the
validity of the SCAPHQ in relation to concurrent ad-
ministration of major clinical and functional instruments for
schizophrenia. We will consider applications of SCAPHQ
in longitudinal studies and present results of its use in this
context. The participant will understand potential appli-
cations of the instrument in research and routine assess-
ment.
PARTICIPANTS WHO WOULD BENEFIT: Providers
of care for schizophrenia and researchers with interest in
methods to measure and monitor outcomes of treatment
in actual care settings.
Schizophrenia affects about one percent of the popula-
tion and exacts substantial human and economic costs.
We will discuss the development, validation, and applica-
tions of a new instrument (SCAPHQ) to assess out-
comes of care for this disease in research or routine clini-
cal assessment. We will address measurement of patients’
disease status (symptoms, side effects), generic health sta-
tus, functional status (productivity, social relations, daily
activities, leisure), quality of life, and safety and welfare.
We will evaluate the instrument’s performance with re-
spect to internal consistency, test-retest reliability, and
criterion validity in comparison to existing instruments.
We will discuss use of the instrument to model the effect
of prior period clinical status, medication therapy, and
other patient characteristics on clinical and functional
outcome. Participants with interest in patient-centered
methods for schizophrenia outcomes assessment will ben-
efit from this workshop.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop is to present Multiple Disease Risk Assessment
2000 (MDRA 2000), a tool for empiric assessment of
disease risk factors, categorization of patients at risk, and
monitoring of patient outcomes.
PARTICIPANTS WHO WOULD BENEFIT: Health-
care decision-makers and others involved in the process
of monitoring and evaluating patient outcomes.
Identifying patients at risk for disease and providing ap-
propriate care can improve patient outcomes and results
in significant cost reductions to healthcare systems. Mul-
tiple Disease Risk Assessment 2000 provides clinicians
with a valuable tool for performing a systematic analysis
of patients at risk of developing a selected disease, infec-
tion, or medical complication. The tool can identify pres-
ence of key risk factors, serve as a guideline for initiating
a therapeutic intervention, and can help identify factors
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associated with adverse events. Patient data can also be
monitored to evaluate financial and clinical outcomes.
MDRA 2000 can serve as a warning system to alert clini-
cians to patients at risk for disease and can assist in the
selecting appropriate strategies for patient management.
The workshop will entail a demonstration of this soft-
ware tool along with an example of risk assessment strat-
egies for a specific disease.
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WORKSHOP OBJECTIVE: The prospective collection
of real-world data on schizophrenia care allows for the
analysis of a broad range of clinical, functional, quality
of life, and economic outcomes. This workshop will: 1)
explore the development of a comprehensive research in-
frastructure for coordination and evaluation of such
data, 2) present the results of analyses conducted on par-
ticipant baseline and physician survey data, and 3) dis-
cuss the use of methodologies for the coordination and
analysis of complex treatment patterns in schizophrenia.
PARTICIPANTS WHO WOULD BENEFIT: Profession-
als who are or expect to be involved in prospective out-
come studies and others interested in the application of
outcomes analyses derived from real-world treatment ex-
periences.
Data on SCAP participants are collected from clinical as-
sessment, self-report, medical records, and administrative
records at 6-month intervals over 3 years. Participants
are being enrolled through six major sites of service deliv-
ery across the United States. The total sample will be
2400 participants. Issues relating to the development of a
coordinated research database and the coordination of
research efforts will be discussed in section one of this
workshop. In section two, the results of baseline analyses
(n  562) conducted on the sample characteristics, on se-
lected clinical, functional, and quality of life outcomes,
and on the impact of those outcomes on service utiliza-
tion will be presented. The factors that facilitate or limit
the adoption and diffusion of new atypical antipsychotics
among physicians treating the SCAP participants (n 
240) will also be discussed. In the final section, a taxo-
nomic approach to the analysis of medication utilization
patterns is discussed within the framework of current
practice, physician behavior, and standards of practice
for the treatment of schizophrenia. Attendees will gain an
understanding of the issues concomitant with collecting,
assessing, and applying the results of prospective data de-
rived from real-world treatment settings.
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WORKSHOP OBJECTIVE: The purpose of this work-
shop is to develop and enhance skills for designing and
conducting pharmacoeconomic analyses of diagnostic
screening and testing (DST). The workshop will focus on
three issues: 1) the nature of the available data on the test
parameters (e.g., sensitivity, specificity), 2) differential
time horizons of the DST alternatives, and 3) the non-
independence of sequential tests.
PARTICIPANTS WHO WOULD BENEFIT: Researchers
in academia and industry who employ pharmacoeconom-
ics to evaluate DST technologies, as well as decision-
makers who must approve these technologies for reim-
bursement.
Pharmacoeconomic analyses of DST technologies can be
more complex than those of medical treatments. Often
the most straightforward decision tree requires probabili-
ties (e.g., the positive and negative predictive values) that
must be calculated from the available test parameters.
What is the correct decision tree structure given available
information? Is Bayesian revision or “tree-flipping” re-
quired? Additionally, analysts may encounter difficulties
when comparing DST alternatives with differential time
horizons. What needs to be considered when comparing
an expensive test that will result in much earlier treat-
ment to a less costly test that takes longer to complete?
Lastly, combinations of sequential tests may be com-
pared to a single test. Given that the individual test re-
sults are no longer independent of each other, how
should the specificity and sensitivity of the individual
tests be modified to account for this? We will employ two
examples to illustrate these issues and demonstrate how
to: 1) identify these problems, 2) appropriately address
them, and 3) present the methods and results to the end-
user of the analysis.
WTG3
WHAT EVERY OUTCOMES RESEARCHER 
SHOULD KNOW ABOUT WOMEN’S 
HEALTH RESEARCH
Frank L1, Greenberger P2, Finnegan L3, Panetta J4
1MEDTAP International, Bethesda, MD, USA; 2Society for the 
Advancement of Women’s Health Research, Washington, DC, 
USA; 3National Institutes of Health, Bethesda, MD, USA; 4Lilly 
Center for Women’s Health, Indianapolis, IN, USA
WORKSHOP OBJECTIVE: This workshop will provide
a brief overview of the field of women’s health research
and ways in which gender-based biology can be incorpo-
rated into general outcomes research, particularly for
clinical trials.
